63 related articles for article (PubMed ID: 22544017)
61. Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies.
Ayan-Oshodi M; Wondmagegnehu ET; Lowe SL; Kryzhanovskaya L; Walker DJ; Kinon BJ
J Clin Psychopharmacol; 2012 Jun; 32(3):408-11. PubMed ID: 22544017
[TBL] [Abstract][Full Text] [Related]
62. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Fell MJ; McKinzie DL; Monn JA; Svensson KA
Neuropharmacology; 2012 Mar; 62(3):1473-83. PubMed ID: 21704048
[TBL] [Abstract][Full Text] [Related]
63. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
Citrome L
Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
